Redey comments on Oncopeptides’ first quarter report 2025. The growth quarter on quarter was 34%, despite a 5% FX headwind. Discussions about a potential deal in Japan are still ongoing. We believe the sales growth trend is stabilising with growing uptake from new markets.
LÄS MER
